Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women

Mansi Dalal, Kai Sun, Anne R. Cappola, Luigi Ferrucci, Candace Crasto, Linda P. Fried, Richard D. Semba

Research output: Contribution to journalArticle


Objective: Although fibroblast growth factor 23 (FGF23) has been implicated in the pathogenesis of cardiovascular disease, the relationship between FGF23 and cardiovascular disease has not been well characterized in the general population. The aim of this study was to determine whether serum FGF23 is independently associated with cardiovascular disease in older community-dwelling women. Design and methods: A cross-sectional design was used to examine the relationship between serum FGF23 and cardiovascular disease. The subjects consisted of a population-based sample of 659 women, aged 70-79 years, who participated in the Women's Health and Aging Studies in Baltimore, Maryland. Prevalent cardiovascular disease (coronary heart disease, stroke, congestive heart failure, and peripheral artery disease) was assessed through diagnostic algorithms and physician adjudication. Results: Of the 659 women, 185 (28.1%) had cardiovascular disease. Median (25th, 75th percentile) intact serum FGF23 was 34.6 (25.2, 46.2) pg/ml. The prevalence of cardiovascular disease in the lowest, middle, and highest tertile of serum FGF23 was 22.6, 24.9, and 36.7% respectively (P=0.002). Serum log FGF23 was associated with cardiovascular disease (odds ratio per 1 S.D. increase=1.23, 95% confidence interval 1.17, 1.30; P

Original languageEnglish (US)
Pages (from-to)797-803
Number of pages7
JournalEuropean Journal of Endocrinology
Issue number5
Publication statusPublished - Nov 2011


ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this